
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is a clinical-stage biopharmaceutical company with a promising portfolio focused on developing innovative and proprietary treatments for Treatment-Resistant Depression (TRD). Despite some potential regulatory and competitive risks, their lead product candidate GH001 has shown impressive efficacy and potential for significant revenue in the US market. With a strong management team and a promising Phase III trial underway, GH Research has a positive outlook for long-term success and potential for significant growth.
Bears say
GH Research is a clinical-stage biopharmaceutical company that was founded in 2018, and while it currently has a strong financial position, with over $362 million in cash, it has significant development, regulatory, and commercial risks ahead. These risks include potential issues with the FDA in lifting the clinical hold on GH001 and potential competition from more efficacious products if GH001 is approved. Further risks include the potential failure to secure financing for the pivotal Phase 3 trial and commercialization. GH Research is focusing on developing therapeutics for psychiatric and neurologic disorders, but the success of its lead product candidates, GH001 and GH002, is uncertain given the significant risks involved in their development and potential competition in the market.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares